GlassScriptPhysician profile
William J Scharpf
NPI 1619471018
$7,696.89
in general payments reported to CMS, 2019-2025
46 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2021: $111 · 2022: $954 · 2023: $2,622 · 2024: $2,318 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,436.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $631.17 | 2023-2025 | |
| Abbvie INC. | $614.91 | 2022-2025 | Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $432.58 | 2022-2025 | Nuplazid |
| Ge Healthcare | $370.47 | 2022-2025 | |
| Horizon Therapeutics Plc | $343.79 | 2022-2023 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $337.80 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $322.13 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Celgene Corporation | $315.15 | 2023-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $307.79 | 2023-2025 | Ultomiris, Soliris |
| Amgen INC. | $294.16 | 2022-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $253.34 | 2022-2025 | |
| Lundbeck LLC | $252.68 | 2022-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $250.91 | 2022-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $239.50 | 2022-2025 | Hyqvia, Gammagard |
| E.R. Squibb & Sons, L.L.C. | $218.75 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $210.14 | 2022-2024 | Gocovri, Gocovri |
| Sk Life Science, INC. | $192.79 | 2022-2025 | Xcopri |
| Argenx US, INC. | $176.79 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $175.39 | 2022-2025 | Mavenclad |
| Ucb, INC. | $157.41 | 2022-2025 | Briviact, Zilbrysq |
| Scilex Pharmaceuticals INC. | $156.54 | 2023-2024 | Ztlido |
| Biogen, INC. | $121.60 | 2023-2024 | Vumerity, Tysabri, Skyclarys |
| Amneal Pharmaceuticals LLC | $118.52 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Janssen Pharmaceuticals, INC | $118.36 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $110.28 | 2023-2024 | Aptiom |
| Azurity Pharmaceuticals, INC. | $105.31 | 2023-2024 | Horizant, Horizant |
| Allergan, INC. | $94.83 | 2019 | |
| Tanabe Pharma America, INC. | $85.84 | 2023-2025 | Radicava |
| Vanda Pharmaceuticals INC. | $73.82 | 2024-2025 | Ponvory |
| Kyowa Kirin, INC. | $70.40 | 2023-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $65.71 | 2022-2023 | Austedo Xr, Austedo |
| Acorda Therapeutics, INC | $64.09 | 2022-2024 | Inbrija, Ampyra |
| C2n Diagnostics, LLC | $59.34 | 2025 | Precivityad2 |
| Banner Life Sciences, LLC | $48.70 | 2023 | |
| Csl Behring | $45.14 | 2023 | Hizentra |
| Eisai INC. | $43.86 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.40 | 2022 | |
| Corium, LLC | $25.70 | 2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $23.25 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $23.23 | 2023 | Firdapse |
| Inspire Medical Systems, INC. | $21.66 | 2025 | Inspire |
| Genzyme Corporation | $20.35 | 2022 | |
| Cycle Pharmaceuticals INC | $17.25 | 2025 | Tascenso Odt |
| Abbott Laboratories | $16.94 | 2023 | Infinity |
| Averitas Pharma INC. | $16.20 | 2025 | Qutenza |
| Impel Pharmaceuticals LLC | $13.92 | 2025 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Scharpf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.